Ocular neovascularization

Ocular neovascularization

Abnormal or excessive formation of blood vessels in the eye.
References in periodicals archive ?
His major laboratory interest is in elucidating the molecular pathogenesis of ocular neovascularization and excessive vascular leakage.
Particular topics covered by the 13 chapters include pathophysiology and clinical implications of vascular endothelial growth factor (VEGF-a signaling protein), signal transduction of VEGF receptors toward angiogenesis, growth factors and lymphangiogenesis, neural guidance molecules in vascular development, non-angiogenic functions of VEGF, contribution of pro-angiogenic hematopoietic cells to vascularization of tumor and ischemic tissues, antiangiogenic drugs as broadly effective chemosensitizing agents, ocular neovascularization, and therapeutic angiogenesis for cardiovascular disease.
Anthony Adamis, MD, associate professor of ophthalmology at Harvard Medical School and director of EyeTech's preclinical development program noted, "Given the requisite role of VEGF in ocular neovascularization and the aptamers' high specificity for VEGF, this aptamer is a logical choice for the inhibition of choroidal neovascularization secondary to AMD.
In preclinical studies involving models of ocular neovascularization, concurrent inhibition of PDGF-B and vascular endothelial growth factor A (VEGF-A) signaling was superior to inhibition of the VEGF-A pathway alone, and demonstrated the potential to induce neovascular regression.
The current partnership will pursue clinical development and commercialization of Sirnaomics' therapeutic product candidate (STP601), for treatment of ocular neovascularization conditions, in the Greater China and Southeast Asia markets.
The leading product, STP601, a multi-targeted siRNA cocktail therapeutics for treatment of ocular neovascularization such as AMD, PDR and HSK, is expected to be in clinic in 2008, in addition to an enriched product pipeline of siRNA therapeutics.
Miller's research interests are focused on ocular neovascularization, particularly as it relates to macular degeneration and diabetic retinopathy, including the role of growth factors, the development of antiangiogenic therapy and photodynamic therapy.
Macugen works by binding to the specific isoform VEGF165, which is believed to be responsible for the pathological blood vessel growth and leakage in ocular neovascularization.
We believe that these new proprietary molecules have the potential to significantly improve clinical outcomes in patients with ocular neovascularization.
VEGF Inhibition Study in Ocular Neovascularization (VISION): Second Year Efficacy Data to be presented during an oral presentation on Tuesday, May 03, 2005 at 8:45 AM - 9:00 AM, by Donald D'Amico M.
By mid-year, the Company expects to file an IND for a topical formulation of ZYBRESTAT and proceed into clinical evaluation of the product candidate in patients with age-related macular degeneration and/or another ophthalmological condition characterized by abnormal ocular neovascularization.
Intradigm's ICS-283 therapeutic inhibiting pro-angiogenic factors has been shown effective by systemic delivery as a candidate treatment for cancer in research published November 1, 2004 by Nucleic Acid Research and as a treatment for ocular neovascularization diseases in research published in the December 2004 issue of American Journal of Pathology.